CDK4 and breast neoplasm: Indeed, our data support the addition of RETi to CDK4/6i and/or endocrine therapy as a therapeutic strategy following resistance to combined CDK4/6i and endocrine therapy in ER+ breast tumors exhibiting RET overexpression.